Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpelisib + Cetuximab in RM HNSCC
NCT01602315Phase 2Terminated
- Sponsor
- Novartis
- Start
- Nov 2012
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, open-label trial of alpelisib in head and neck squamous cell carcinoma (HNSCC) (7 arms), sponsored by Novartis. Primary endpoints: Probability That Dose Limiting Toxicities (DLTs) Rate is in the Recommended Phase 2 Dose in Cycle 1, Incidence of Dose Limiting Toxicities (DLTs) in Cycle 1 and 2 more. Started Nov 2012; status: terminated.
02
Drugs
alpelisib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT01602315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01602315.